Donepezil 23 mg/day vs donepezil 10 mg/day
Change in MMSE · people with Alzheimer's disease
1 finding from 1 review
- no estimate extracted1 study · 1370 participantsModerate
Findings
What do systematic reviews say?
3,454 questions · 3,562 findings · 816 reviews · Headline outcomes only
No studies found 538 · 15.1%GRADE not reported 239 · 6.7%Very low 933 · 26.2%Low 1,041 · 29.2%Moderate 612 · 17.2%High 199 · 5.6%
Donepezil 23 mg/day vs donepezil 10 mg/day
Change in capacity for activities of daily living · people with Alzheimer's disease
1 finding from 1 review
- no estimate extracted1 study · 1396 participantsModerate
Donepezil 23 mg/day vs donepezil 10 mg/day
Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) · people with Alzheimer's disease
Donepezil 23 mg/day showed no clear difference in clinician‐rated global impression test (improved compared with… compared with donepezil 10 mg/day (moderate certainty).
1 finding from 1 review
- OR 0.99 [0.78, 1.26]2 studies · 1704 participantsModerate
Donepezil 23 mg/day vs donepezil 10 mg/day
Secondary outcome: acceptability of treatment · people with Alzheimer's disease
Donepezil 23 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with donepezil 10 mg/day (moderate certainty).
1 finding from 1 review
- OR 2.02 [1.59, 2.57]2 studies · 1818 participantsModerate
Donepezil 23 mg/day vs donepezil 10 mg/day
Risk for at least one adverse event per patient · people with Alzheimer's disease
Donepezil 23 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with donepezil 10 mg/day (moderate certainty).
1 finding from 1 review
- OR 1.65 [1.34, 2.03]2 studies · 1785 participantsModerate
Donepezil 10 mg/day vs donepezil 5 mg/day
Change in ADAS‐Cog · people with Alzheimer's disease
1 finding from 1 review
- no estimate extracted2 studies · 818 participantsModerate
Donepezil 10 mg/day vs donepezil 5 mg/day
Change in MMSE · people with Alzheimer's disease
1 finding from 1 review
- no estimate extracted1 study · 303 participantsModerate
Donepezil 10 mg/day vs donepezil 5 mg/day
Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) · people with Alzheimer's disease
Donepezil 10 mg/day showed no clear difference in clinician‐rated global impression test (improved compared with… compared with donepezil 5 mg/day (moderate certainty).
1 finding from 1 review
- OR 1.26 [0.94, 1.67]3 studies · 981 participantsModerate
Donepezil 10 mg/day vs donepezil 5 mg/day
Secondary outcome: acceptability of treatment · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with donepezil 5 mg/day (moderate certainty).
1 finding from 1 review
- OR 1.67 [1.24, 2.23]3 studies · 1052 participantsModerate
Donepezil 10 mg/day vs donepezil 5 mg/day
Risk for at least one adverse event per patient · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with donepezil 5 mg/day (moderate certainty).
1 finding from 1 review
- OR 1.56 [1.07, 2.28]2 studies · 741 participantsModerate
Donepezil 23 mg/day vs donepezil 10 mg/day
Cognitive function · people with Alzheimer's disease
1 finding from 1 review
- no estimate extracted2 studies · 1704 participantsModerate
10‐day trimethoprim vs 10‐day trimethoprim+sulfamethoxazole
Persistent bacteriuria · children with lower urinary tract infection
It is very uncertain whether 10‐day trimethoprim changes persistent bacteriuria compared with 10‐day trimethoprim+sulfamethoxazole (very low certainty).
1 finding from 1 review
- Antibiotics for treating lower urinary tract infection in children 2012 · Cochrane Headline outcomes onlyRR 1.93 [0.38, 9.76]1 study · 59 participantsVery low
10‐day trimethoprim vs 10‐day trimethoprim+sulfamethoxazole
Persistent symptoms · children with lower urinary tract infection
It is very uncertain whether 10‐day trimethoprim changes persistent symptoms compared with 10‐day trimethoprim+sulfamethoxazole (very low certainty).
1 finding from 1 review
- Antibiotics for treating lower urinary tract infection in children 2012 · Cochrane Headline outcomes onlyRR 4.84 [0.24, 96.66]1 study · 59 participantsVery low
10‐day trimethoprim vs 10‐day trimethoprim+sulfamethoxazole
Recurrence · children with lower urinary tract infection
It is very uncertain whether 10‐day trimethoprim changes recurrence compared with 10‐day trimethoprim+sulfamethoxazole (very low certainty).
1 finding from 1 review
- Antibiotics for treating lower urinary tract infection in children 2012 · Cochrane Headline outcomes onlyRR 2.9 [0.12, 68.5]1 study · 59 participantsVery low
Primaquine five days vs 14 days
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
- Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine 2013 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 186 participantsGRADE not reported
Primaquine five days vs 14 days
Other adverse events · People with P. vivax malaria1
1 finding from 1 review
- Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine 2013 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 186 participantsGRADE not reported
Day‐surgery vs overnight stay surgery
Short term mortality · patients with laparoscopic cholecystectomy.
1 finding from 1 review
- Day‐surgery versus overnight stay surgery for laparoscopic cholecystectomy 2013 · Cochrane Headline outcomes onlyno estimate extracted1 study · 86 participantsLow
Day‐surgery vs overnight stay surgery
Serious adverse events · patients with laparoscopic cholecystectomy.
It is very uncertain whether day‐surgery changes serious adverse events compared with overnight stay surgery (very low certainty).
1 finding from 1 review
- Day‐surgery versus overnight stay surgery for laparoscopic cholecystectomy 2013 · Cochrane Headline outcomes onlyRate Ratio 3.24 [0.74, 14.09]4 studies · 391 participantsVery low
Day‐surgery vs overnight stay surgery
Quality of life · patients with laparoscopic cholecystectomy.
It is very uncertain whether day‐surgery changes quality of life compared with overnight stay surgery (very low certainty).
1 finding from 1 review
- Day‐surgery versus overnight stay surgery for laparoscopic cholecystectomy 2013 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 333 participantsVery low
Day‐surgery vs overnight stay surgery
Pain · patients with laparoscopic cholecystectomy.
1 finding from 1 review
- Day‐surgery versus overnight stay surgery for laparoscopic cholecystectomy 2013 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 175 participantsVery low